|
de Bono J.S., Williams A., Melero I., Jayaram A., Hawley J.E., de Speville B.D., Moreno I., Castellano D., Reig Ò., Knapen D.G., Anguera G., Martinez J., Gort E., de Jonge M., Alonso-Romero J.L., Boni V., Perez-Gracia J.L., Falcon A., de Groot D.J., Pierce A.J., Leishman A.J., Lloyd P., Bartlett P.D., Bland-Ward P., Chau A., Song M., Duffy K., Hashimoto K., de Vries E. A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors. Clinical Cancer Research. 15 August 2025. 31:3388-3399. 10.1158/1078-0432.CCR-24-3581
AÑO: 2025; IF: 10.2
|
|
Encarnación J.A., Morillo Macías V., De la Fuente Muñoz I., Soria V.D., Fernández Fornos L., Antequera M.A., Rey O.A., García Martínez V., Alonso-Romero J.L., García Gómez R. Apalutamide and Stereotactic Body Radiotherapy in Metastatic Hormone-Sensitive Prostate Cancer: Multicenter Real-World Study. Cancers. July 2025. 17. 10.3390/cancers17132216
AÑO: 2025; IF: 4.4
|
|
Agrawal Y.N., Fernández-Martnez A., Gil-Gil M., Zielinski C., Ruiz-Borrego M., Ciruelos E.M., Muñoz M., Margel M., Bermejo B., Antón A., Kahan Z., Csöszi T., Alonso-Romero J.L., Garca-Saenz J.Á., Sánchez-Rovira P., Álvarez E., Chacón J.I., González-Santiago S., Rodrguez C.A., Servitja S., Pfefferle A.D., Herranz J., Liu Y., Carey L.A., Romero-Camarero I., Caballero R., Guerrero-Zotano Á., Perou C.M., Martn M. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. JCO Precision Oncology. 1 July 2025. 9. 10.1200/PO-24-00937
AÑO: 2025; IF: 5.6
|
|
Encarnacion JA, Lopez-Jimenez E, Alonso-Romero JL, Ruiz P, Ros S, De la Fuente MI, Lopez F, Cardenas E, Laborda A, Sanchez-Perez M, Rodriguez C, Manso C, Ortega-Lopez ND, Lopez-Cubillana P, Guzman Martinez-Valls PL, Cao-Avellaneda E, Lopez-Gonzalez PA, Lopez-Abad A. Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve. Cancers (Basel). 2025 Dec 13;17(24):3977. doi: 10.3390/cancers17243977. PubMed PMID: 41463226; PubMed Central PMCID: PMC12730855.
AÑO: 2025; IF: 4.4
|
|
Encarnacion JA, Morillo Macias V, De la Fuente Munoz I, Soria VD, Fernandez Fornos L, Antequera MA, Rey OA, Garcia Martinez V, Alonso-Romero JL, Garcia Gomez R. Apalutamide and Stereotactic Body Radiotherapy in Metastatic Hormone-Sensitive Prostate Cancer: Multicenter Real-World Study. Cancers (Basel). 2025 Jul 2;17(13):2216. doi: 10.3390/cancers17132216. PubMed PMID: 40647514; PubMed Central PMCID: PMC12249003.
AÑO: 2025; IF: 4.4
|